We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. A study looked at real-world outcomes with Omni, Hydrus, ...
A Meta-Analysis of 22 Studies, and Data from the IRIS® Registry Highlighting Clinical Outcomes in Real-World Clinical Practice, Demonstrates Significant, Long-Term IOP Reduction and Medication ...
Sight Sciences Inc. (NASDAQ:SGHT) on Tuesday announced that UnitedHealthcare has updated its Glaucoma Surgical Treatments policy to cover goniotomy, trabeculotomy, canaloplasty (ab interno), and ...
Sight Sciences, Inc. has announced that new data on the OMNI® Surgical System will be presented at the 2025 American Glaucoma Society Annual Meeting, showcasing significant clinical outcomes in ...
MENLO PARK, Calif., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Sight Sciences (SGHT), Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and ...
MENLO PARK, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing ...
MENLO PARK, Calif., May 06, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (SGHT) (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative technology that ...
MENLO PARK, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results